Researchers in Sweden compared mortality (death) rates among rheumatoid arthritis patients treated with one of three TNF blockers -- Enbrel, Remicade, or Humira. In Sweden, about 15% of rheumatoid arthritis patients are prescribed TNF blockers. Between 2003 and 2008, 1,609 rheumatoid arthritis patients were treated with Humira, 2,686 with Enbrel, and 2,027 with Remicade. It was their first exposure to biologic drugs.
During the 5-year study period, 211 patients (3.3%) died. According to study results published online August 8, 2012 in Arthritis & Rheumatism, there was no significant difference found in the mortality rates of patients treated with the three biologic drugs studied.
- TNF-alpha Blockers - What You Need to Know
- The Facts of Enbrel
- The Facts of Remicade
- The Facts of Humira
Photo © Abbott Laboratories